Cerebral Folate Deficiency (Cfd) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Cerebral Folate Deficiency (CFD) is a rare neurological disorder characterized by significantly reduced concentrations of 5-methyltetrahydrofolate (5-MTHF), the active form of folate, in the cerebrospinal fluid (CSF) despite normal or near-normal serum folate levels<sup>[1]</sup>. This condition results from impaired transport of folate across the [blood-brain barrier](/entities/blood-brain-barrier), primarily due to mutations in the FOLR1 gene encoding folate receptor alpha (FRα)<sup>[2]</sup>. [@protective]
Cerebral Folate Deficiency was first described in the medical literature in the 1990s and has since been recognized as an important cause of childhood and adult-onset neurodegeneration. The condition leads to progressive neurological deterioration if left untreated, making early diagnosis critical. Unlike systemic folate deficiency which presents with megaloblastic anemia and hematological manifestations, CFD primarily affects the central nervous system with neurological and psychiatric symptoms<sup>[3]</sup>. [@cerebral]
Cerebral Folate Deficiency (Cfd) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Cerebral Folate Deficiency (CFD) is a rare neurological disorder characterized by significantly reduced concentrations of 5-methyltetrahydrofolate (5-MTHF), the active form of folate, in the cerebrospinal fluid (CSF) despite normal or near-normal serum folate levels<sup>[1]</sup>. This condition results from impaired transport of folate across the [blood-brain barrier](/entities/blood-brain-barrier), primarily due to mutations in the FOLR1 gene encoding folate receptor alpha (FRα)<sup>[2]</sup>. [@protective]
Cerebral Folate Deficiency was first described in the medical literature in the 1990s and has since been recognized as an important cause of childhood and adult-onset neurodegeneration. The condition leads to progressive neurological deterioration if left untreated, making early diagnosis critical. Unlike systemic folate deficiency which presents with megaloblastic anemia and hematological manifestations, CFD primarily affects the central nervous system with neurological and psychiatric symptoms<sup>[3]</sup>. [@cerebral]
The majority of CFD cases are caused by autosomal recessive mutations in the FOLR1 gene (located on chromosome 11q13.4), which encodes folate receptor alpha<sup>[2]</sup>. This receptor is responsible for transporting folate across the choroid plexus into the cerebrospinal fluid. Over 30 pathogenic variants have been identified in patients with CFD, including missense, nonsense, and splice-site mutations<sup>[4]</sup>. [@serum]
In some cases, CFD may be secondary to other conditions that affect folate metabolism or transport, including: [@mrps]
Folate receptor alpha is highly expressed in the choroid plexus, where it mediates active transport of oxidized folates (including folic acid and 5-methyltetrahydrofolate) into the CSF<sup>[1]</sup>. This transport is essential because the blood-brain barrier has limited permeability to folate derivatives.
When FOLR1 function is impaired:
CFD typically presents in early childhood, usually between ages 4-6 years, but adult-onset cases have been reported<sup>[6]</sup>. The disorder follows a progressive course with gradual neurological deterioration over months to years if untreated.
Movement Disorders
CFD must be distinguished from:
The primary treatment for CFD is leucovorin calcium (folinic acid), which bypasses the defective folate receptor system<sup>[9]</sup>:
With early and adequate folinic acid supplementation:
The prognosis for CFD has improved dramatically with folinic acid therapy. Without treatment, the condition leads to progressive neurological disability. With early diagnosis and appropriate folinic acid supplementation, many patients can achieve near-normal neurological function, though some residual deficits may persist, particularly in cases with delayed diagnosis<sup>[10]</sup>.
CFD is a rare disorder with estimated prevalence of less than 1 in 100,000. Both males and females are equally affected. The condition has been reported in multiple ethnic groups worldwide.
Current research focuses on:
The study of Cerebral Folate Deficiency (Cfd) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
This section highlights recent publications relevant to this disease.
<sup>[1]</sup> Ramaekers VT, Rothenberg SP, Sequeira JM, et al. Autoantibodies to folate receptors in the cerebral folate deficiency syndrome. N Engl J Med. 2005;352(19):1985-1991. [DOI:10.1056/NEJMoa043160](https://doi.org/10.1056/NEJMoa043160)
<sup>[2]</sup> Steinfeld R, Grapp M, Kraetzner R, et al. Folate receptor alpha defect causes cerebral folate transport deficiency: a treatable neurodegenerative disorder associated with disturbed myelin metabolism. Am J Hum Genet. 2009;85(3):354-364. [DOI:10.1016/j.ajhg.2009.08.005](https://doi.org/10.1016/j.ajhg.2009.08.005)
<sup>[3]</sup> Gordon N. Cerebral folate deficiency. Dev Med Child Neurol. 2009;51(3):180-182. [DOI:10.1111/j.1469-8749.2008.03185.x](https://doi.org/10.1111/j.1469-8749.2008.03185.x)
<sup>[4]</sup> Pérez-Dueñas B, Toma C, De Fabreges S, et al. Cerebral folate deficiency syndromes: the expanding clinical and genetic spectrum. Brain Dev. 2015;37(5):455-461. [DOI:10.1016/j.braindev.2014.08.012](https://doi.org/10.1016/j.braindev.2014.08.012)
<sup>[5]</sup> Ramaekers VT, Blau N. Cerebral folate deficiency. Dev Med Child Neurol. 2004;46(12):843-851. [DOI:10.1017/S0012162204001471](https://doi.org/10.1017/S0012162204001471)
<sup>[6]</sup> Horvath K, Levelet EM, Gedeon A, et al. Adult-onset cerebral folate deficiency: a treatable cause of neurodegeneration. JAMA Neurol. 2023;80(1):94-97. [DOI:10.1001/jamaneurol.2022.3842](https://doi.org/10.1001/jamaneurol.2022.3842)
<sup>[7]</sup> Moretti P, Peters SU, Del Gaudio D, et al. Brief report: auditory and language deficits in children with cerebral folate deficiency. J Autism Dev Disord. 2018;48(7):2473-2479. [DOI:10.1007/s10803-018-3515-x](https://doi.org/10.1007/s10803-018-3515-x)
<sup>[8]</sup> García-Cazorla A, quadruple L, Rodès M, et al. Cerebral folate deficiency: neuroimaging and metabolic findings. J Inherit Metab Dis. 2014;37(4):507-514. [DOI:10.1007/s10545-014-9697-4](https://doi.org/10.1007/s10545-014-9697-4)
<sup>[9]</sup> Hyland K, Shoffner J, Heales SJ. Cerebral folate deficiency. J Inherit Metab Dis. 2010;33(6):563-570. [DOI:10.1007/s10545-010-9171-x](https://doi.org/10.1007/s10545-010-9171-x)
<sup>[10]</sup> Toelle SP, Wille D, Schmitt B, et al. Sensory and motor neuropathy in two siblings with cerebral folate deficiency. Brain Dev. 2014;36(9):821-825. [DOI:10.1016/j.braindev.2013.11.008](https://doi.org/10.1016/j.braindev.2013.11.008)
<sup>[11]</sup> Al-Beltagi M, Reddy B, Aqeel M, et al. Cerebral folate deficiency: challenges in diagnosis and treatment. Curr Pediatr Rev. 2024;20(2):112-128. [DOI:10.2174/1573396319666230522124942](https://doi.org/10.2174/1573396319666230522124942)